Eiger BioPharmaceuticals (STU:72C) Total Liabilities: €48.86 Mil (As of Dec. 2023)


STU:72C Eiger BioPharmaceuticals Inc STU:72C
10 GF Score
Price €6.18
View Full Analysis

What is Eiger BioPharmaceuticals Total Liabilities?

Eiger BioPharmaceuticals STU:72C 10 Total Liabilities is €48.86 Mil as of Dec. 2023. GuruFocus rates STU:72C with a GF Score™ of 10/100.

Eiger BioPharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was €48.86 Mil.

Eiger BioPharmaceuticals's quarterly Total Liabilities declined from Dec. 2022 (€61.20 Mil) to Jun. 2023 (€52.67 Mil) and declined from Jun. 2023 (€52.67 Mil) to Dec. 2023 (€48.86 Mil).

Eiger BioPharmaceuticals's annual Total Liabilities increased from Dec. 2021 (€47.79 Mil) to Dec. 2022 (€61.20 Mil) but then declined from Dec. 2022 (€61.20 Mil) to Dec. 2023 (€48.86 Mil).

Eiger BioPharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Eiger BioPharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eiger BioPharmaceuticals Total Liabilities Chart

Eiger BioPharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.79 39.92 47.79 61.20 48.86

Eiger BioPharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.49 61.20 52.67 48.86 50.21
STU:72C
10GF Score
Eiger BioPharmaceuticals Inc STU:72C
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eiger BioPharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Eiger BioPharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=48.861+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=48.86

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=35.603--13.258
=48.86

Eiger BioPharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=48.861+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=48.86

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=35.603--13.258
=48.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €48.86 Mil mean?
Eiger BioPharmaceuticals (STU:72C) has a Total Liabilities of €48.86 Mil as of Dec. 2023. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Eiger BioPharmaceuticals and its competitors.
Is Eiger BioPharmaceuticals' Total Liabilities too high?
Eiger BioPharmaceuticals' current Total Liabilities is €48.86 Mil. Overall, Eiger BioPharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Eiger BioPharmaceuticals' Total Liabilities compare to EDSA and SIGY?
Eiger BioPharmaceuticals' Total Liabilities of €48.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Eiger BioPharmaceuticals and its competitors. Eiger BioPharmaceuticals's current Total Liabilities is €48.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiger BioPharmaceuticals stock overvalued right now?
Eiger BioPharmaceuticals (STU:72C) has a current Total Liabilities of €48.86 Mil. The current Total Liabilities is €48.86 Mil. Eiger BioPharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Eiger BioPharmaceuticals (STU:72C), the current Total Liabilities is €48.86 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eiger BioPharmaceuticals Business Description

Address 2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
10GF Score

Get the complete analysis for STU:72C

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.18
Price